| Dan S Powell, MD | |
|
1607 S Locust Ave, Lawrenceburg, TN 38464-4011 | |
| (931) 762-6571 | |
| (865) 291-3228 |
| Full Name | Dan S Powell |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 1607 S Locust Ave, Lawrenceburg, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952340697 | NPI | - | NPPES |
| 890-26075 | Other | AL | BCBS |
| 4122502 | Other | TN | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 37716 (Tennessee) | Primary |
| Entity Name | Southeastern Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356379382 PECOS PAC ID: 2466364997 Enrollment ID: O20050125000997 |
News Archive
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
You've just gotten your summer routine dialed in, and you have to think about how to keep fall allergies at bay? Yes. But the good news is if you start planning now, your allergy symptoms will likely be much less severe, and you'll be able to enjoy the beauty the fall season brings.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
› Verified 2 days ago
| Entity Name | Emergency Coverage Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427005008 PECOS PAC ID: 3072412592 Enrollment ID: O20050207000666 |
News Archive
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
You've just gotten your summer routine dialed in, and you have to think about how to keep fall allergies at bay? Yes. But the good news is if you start planning now, your allergy symptoms will likely be much less severe, and you'll be able to enjoy the beauty the fall season brings.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
› Verified 2 days ago
| Entity Name | Southeastern Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083835441 PECOS PAC ID: 0042307852 Enrollment ID: O20071025000571 |
News Archive
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
You've just gotten your summer routine dialed in, and you have to think about how to keep fall allergies at bay? Yes. But the good news is if you start planning now, your allergy symptoms will likely be much less severe, and you'll be able to enjoy the beauty the fall season brings.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
› Verified 2 days ago
| Entity Name | App Of Tennessee Ed Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003230236 PECOS PAC ID: 8123251766 Enrollment ID: O20140506000159 |
News Archive
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
You've just gotten your summer routine dialed in, and you have to think about how to keep fall allergies at bay? Yes. But the good news is if you start planning now, your allergy symptoms will likely be much less severe, and you'll be able to enjoy the beauty the fall season brings.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dan S Powell, MD Po Box 636019, Cincinnati, OH 45263-6019 Ph: () - | Dan S Powell, MD 1607 S Locust Ave, Lawrenceburg, TN 38464-4011 Ph: (931) 762-6571 |
News Archive
Celsis International Ltd. announced today that Celsis In Vitro, Inc. has reached a settlement agreement with XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a patent infringement lawsuit filed by Celsis IVT on February 2, 2010.
You've just gotten your summer routine dialed in, and you have to think about how to keep fall allergies at bay? Yes. But the good news is if you start planning now, your allergy symptoms will likely be much less severe, and you'll be able to enjoy the beauty the fall season brings.
Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.
At present, a focus on males in basic research and clinical trials means that models of disease are also based on men. Symptoms and disease progression in male patients are therefore considered the standard, while disease manifestations that are usually observed in women are judged "atypical".
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration has approved ILUVIEN for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
› Verified 2 days ago
Dr. Krystal V Garcia, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1607 S Locust Ave, Lawrenceburg, TN 38464 Phone: 912-539-5587 | |
William L Bell Jr., MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1607 S Locust Ave, Lawrenceburg, TN 38464 Phone: 931-762-6571 Fax: 865-291-3228 | |
Charles Love, MD Emergency Medicine Medicare: May Accept Medicare Assignments Practice Location: 1607 S Locust Ave, Lawrenceburg, TN 38464 Phone: 931-762-6571 Fax: 865-291-3228 |